Kintara Therapeutics Inc (NASDAQ:KTRA) (OTCMKTS:DMPWW) (FRA:3DM), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, has announced its addition to the Russell Microcap Index.
The company said its addition will take place at the conclusion of the 2021 Russell Indexes' annual reconstitution, effective after the US market opens on June 28, according to a preliminary list of additions posted on June 4.
"We are delighted for Kintara to have been added to the FTSE Russell Microcap Index, which will help increase investor exposure to our company's mission of developing novel cancer therapies for patients with unmet medical needs," said CEO Saiid Zarrabian in a statement.
READ: Kintara Therapeutics enrolls last patient in Phase 2 VAL-083 trial for glioblastoma multiforme
"We look forward to the opportunity to expand awareness of our late-stage oncology pipeline of which our lead product, VAL-083, is currently being tested in GCAR's GBM AGILE registrational study for all three GBM patient subtypes of newly-diagnosed methylated MGMT, newly-diagnosed unmethylated MGMT, and recurrent GBM."
Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell Indexes primarily by objective, market-capitalization rankings, and style attributes.
Russell Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. About $10.6 trillion in assets are benchmarked against Russell's US Indexes, which are part of FTSE Russell, a leading global index provider.
Located in San Diego, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham